Blockchain Registration Transaction Record

Lantern Pharma's LP-184 Gets EMA Nod for Bladder Cancer Trial

Lantern Pharma (LTRN) announces EMA clearance for Phase 1b/2 trial of LP-184 in bladder cancer. AI-driven precision oncology using RADR platform. Learn about the trial and withZeta.ai.

This news matters because it represents a potential new treatment option for patients with advanced or metastatic bladder cancer who have exhausted standard therapies. Lantern's AI-driven approach, using biomarkers like PTGR1 overexpression, could enable more precise patient selection and improve trial success rates. Additionally, the commercial launch of withZeta.ai provides a powerful tool for the global biomedical community, accelerating drug discovery and potentially leading to faster, more effective cancer treatments.